传统细胞毒性化疗相关肾毒性:第34届ADQI工作组共识报告
该共识报告聚焦肿瘤肾脏病学中传统细胞毒性化疗药物的肾毒性,重点讨论顺铂、异环磷酰胺、甲氨蝶呤、培美曲塞、吉西他滨、美法仑和丝裂霉素C。报告系统综述了每种药物的肾毒性流行病学、机制、危险因素、临床表现、预防与管理,并提出研究议程以填补知识空白。
要点
- 常见肾毒性化疗药包括顺铂、异环磷酰胺、甲氨蝶呤、培美曲塞、吉西他滨、美法仑和丝裂霉素C。
- 肾毒性可表现为急性肾损伤和慢性肾脏病,需关注预防与管理。
- 共识报告涵盖流行病学、机制、危险因素、临床表现及防治策略。
核心结论
- 传统细胞毒性化疗药物可导致急性和慢性肾损伤,临床需重视其肾毒性。
研究设计与样本
- 第34届急性疾病质量倡议(ADQI)工作组共识报告,聚焦传统细胞毒性化疗肾毒性。
主要发现
- 重点讨论顺铂、异环磷酰胺、甲氨蝶呤、培美曲塞、吉西他滨、美法仑和丝裂霉素C的肾毒性。
- 报告涵盖每种药物的肾毒性流行病学、机制、危险因素、临床表现、预防和管理。
临床怎么用
- 临床应识别高危患者,监测肾功能,并采取预防和管理措施以减少肾毒性。
局限性
- 共识报告基于现有证据,指出知识空白并呼吁进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The subfield of onconephrology has rapidly grown with the proliferation of highly effective cancer therapies and the remarkable improvement in patient survival. Conventional cytotoxic chemotherapy is the backbone of cancer therapy, often used alone or with targeted agents and immunotherapies. However, beneficial anticancer effects are often complicated by nephrotoxicity, which includes acute and chronic kidney injury. Although numerous conventional cytotoxic chemotherapy drugs are nephrotoxic, some of the most common offenders that clinicians encounter are cisplatin, ifosfamide, methotrexate, pemetrexed, gemcitabine, melphalan, and mitomycin C. They will be the focus of this review. This Acute Disease Quality Initiative Consensus Conference Workgroup covered cytotoxic chemotherapy nephrotoxicity and reviewed several aspects of their adverse kidney complications. Included are (i) epidemiology of each agent's nephrotoxicity, (ii) mechanisms of nephrotoxicity, (iii) predisposing risk factors, (iv) clinical manifestations of nephrotoxicity, (v) prevention and management of kidney injury, and (vi) research agenda addressing knowledge gaps for the noted nephrotoxic cytotoxic chemotherapy.
引用
- Lentini P, Whitman A, Jaimes E, et al. Conventional cytotoxic chemotherapy-associated nephrotoxicity: consensus report of the 34th Acute Disease Quality Initiative (ADQI) Workgroup. Kidney Int. 2026. PMID: 41881107. doi:10.1016/j.kint.2026.01.037
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。